drugset / Trial / NCT03905265

Dose-finding Study of Moxidectin for Treatment of Scabies

NCT03905265

Phase 2 Completed 22 enrolled Medicines Development for Global Health
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The effective dose of moxidectin to treat human scabies is not known. This study aims to provide proof of concept that a single dose of moxidectin is effective in eliminating the scabies parasite in humans and to enable the determination of an optimal dose of moxidectin for treatment of scabies for further clinical studies.

Timeline

Start
2020-01-13
Primary completion
2022-02-28
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxidectin Other / unclassified 2 mg Oral
Subject Moxidectin Other / unclassified 8 mg Oral
Subject Moxidectin Other / unclassified 20 mg Oral
Subject Moxidectin Other / unclassified 36 mg Oral

Indications